Compare RZLT & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RZLT | OABI |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.4M | 277.8M |
| IPO Year | N/A | N/A |
| Metric | RZLT | OABI |
|---|---|---|
| Price | $3.31 | $1.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $9.14 | $6.67 |
| AVG Volume (30 Days) | ★ 4.6M | 364.1K |
| Earning Date | 02-10-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $21,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $66.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 3.36 |
| 52 Week Low | $1.07 | $1.22 |
| 52 Week High | $11.46 | $4.02 |
| Indicator | RZLT | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 42.34 |
| Support Level | $2.69 | $1.76 |
| Resistance Level | $3.59 | $2.10 |
| Average True Range (ATR) | 0.28 | 0.09 |
| MACD | 0.27 | -0.01 |
| Stochastic Oscillator | 75.71 | 20.59 |
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.